Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

B Coiffier; B Pro; HM Prince; F Foss; L Sokol; M Greenwood; D Caballero; P Borchmann; F Morschhauser; Martin Wilhelm; L Pinter-Brown; S Padmanabhan; A Shustov; J Nichols; S Carroll; J Balser; B Balser; S Horwitz

doi:10.1200/JCO.2011.37.4223

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

B Coiffier, B Pro, HM Prince, F Foss, L Sokol, M Greenwood, D Caballero, P Borchmann, F Morschhauser, Martin Wilhelm (Co-author), L Pinter-Brown, S Padmanabhan, A Shustov, J Nichols, S Carroll, J Balser, B Balser, S Horwitz

Research output: Contribution to journal › Original Article › peer-review

547 Citations (Web of Science)

Original language	English
Pages (from-to)	631-636
Journal	JOURNAL OF CLINICAL ONCOLOGY
Volume	30
Issue number	6
DOIs	https://doi.org/10.1200/JCO.2011.37.4223
Publication status	Published - 2012

Keywords

HISTONE DEACETYLASE INHIBITORS
NON-HODGKINS-LYMPHOMAS
REAL CLASSIFICATION
CANCER
DEPSIPEPTIDE
MANAGEMENT

Access to Document

10.1200/JCO.2011.37.4223

Cite this

Coiffier, B., Pro, B., Prince, HM., Foss, F., Sokol, L., Greenwood, M., Caballero, D., Borchmann, P., Morschhauser, F., Wilhelm, M., Pinter-Brown, L., Padmanabhan, S., Shustov, A., Nichols, J., Carroll, S., Balser, J., Balser, B., & Horwitz, S. (2012). Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. JOURNAL OF CLINICAL ONCOLOGY , 30(6), 631-636. https://doi.org/10.1200/JCO.2011.37.4223

Coiffier, B ; Pro, B ; Prince, HM et al. / Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. In: JOURNAL OF CLINICAL ONCOLOGY 2012 ; Vol. 30, No. 6. pp. 631-636.

@article{1bfc45cb9c08454684f21e7a249dc283,

title = "Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy",

keywords = "HISTONE DEACETYLASE INHIBITORS, NON-HODGKINS-LYMPHOMAS, REAL CLASSIFICATION, CANCER, DEPSIPEPTIDE, MANAGEMENT",

author = "B Coiffier and B Pro and HM Prince and F Foss and L Sokol and M Greenwood and D Caballero and P Borchmann and F Morschhauser and Martin Wilhelm and L Pinter-Brown and S Padmanabhan and A Shustov and J Nichols and S Carroll and J Balser and B Balser and S Horwitz",

note = "Bertrand Coiffier, Hospices Civils de Lyon, Lyon; Franck Horschhauser, Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; H. Miles Prince, Peter MacCallum Cancer Centre, East Melbourne; H. Miles Prince, University of Melbourne, Parkville, Melbourne; Matthew Greenwood, Royal North Shore Hospital, Sydney, Australia; Francine Foss, Yale Cancer Center, New Haven, CT; Lubomir Sokol, Moffitt Cancer Center, Tampa, FL; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca, Spain; Peter Borchmann, Klinikum der Universita{\" }t zu K{\"o}ln, Koln; Martin Wilhelm, Klinikum Nu{\" } rnberg Nord, Nu{\" } rnberg, Germany; Lauren Pinter-Brown, University of California at Los Angeles Medical Center, Los Angeles, CA; Swaminathan Padmanabhan, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Andrei Shustov, University of Washington, Seattle, WA; Jean Nichols and Susan Carroll, Celgene, Cambridge, MA; John Balser and Barbara Balser, Veristat, Holliston, MA; and Steven Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY.",

year = "2012",

doi = "10.1200/JCO.2011.37.4223",

language = "English",

volume = "30",

pages = "631--636",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins ",

number = "6",

}

Coiffier, B, Pro, B, Prince, HM, Foss, F, Sokol, L, Greenwood, M, Caballero, D, Borchmann, P, Morschhauser, F, Wilhelm, M, Pinter-Brown, L, Padmanabhan, S, Shustov, A, Nichols, J, Carroll, S, Balser, J, Balser, B & Horwitz, S 2012, 'Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy', JOURNAL OF CLINICAL ONCOLOGY , vol. 30, no. 6, pp. 631-636. https://doi.org/10.1200/JCO.2011.37.4223

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. / Coiffier, B; Pro, B; Prince, HM et al.
In: JOURNAL OF CLINICAL ONCOLOGY , Vol. 30, No. 6, 2012, p. 631-636.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

AU - Coiffier, B

AU - Pro, B

AU - Prince, HM

AU - Foss, F

AU - Sokol, L

AU - Greenwood, M

AU - Caballero, D

AU - Borchmann, P

AU - Morschhauser, F

AU - Wilhelm, Martin

AU - Pinter-Brown, L

AU - Padmanabhan, S

AU - Shustov, A

AU - Nichols, J

AU - Carroll, S

AU - Balser, J

AU - Balser, B

AU - Horwitz, S

N1 - Bertrand Coiffier, Hospices Civils de Lyon, Lyon; Franck Horschhauser, Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; H. Miles Prince, Peter MacCallum Cancer Centre, East Melbourne; H. Miles Prince, University of Melbourne, Parkville, Melbourne; Matthew Greenwood, Royal North Shore Hospital, Sydney, Australia; Francine Foss, Yale Cancer Center, New Haven, CT; Lubomir Sokol, Moffitt Cancer Center, Tampa, FL; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca, Spain; Peter Borchmann, Klinikum der Universita ̈t zu Köln, Koln; Martin Wilhelm, Klinikum Nu ̈ rnberg Nord, Nu ̈ rnberg, Germany; Lauren Pinter-Brown, University of California at Los Angeles Medical Center, Los Angeles, CA; Swaminathan Padmanabhan, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Andrei Shustov, University of Washington, Seattle, WA; Jean Nichols and Susan Carroll, Celgene, Cambridge, MA; John Balser and Barbara Balser, Veristat, Holliston, MA; and Steven Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY.

PY - 2012

Y1 - 2012

KW - HISTONE DEACETYLASE INHIBITORS

KW - NON-HODGKINS-LYMPHOMAS

KW - REAL CLASSIFICATION

KW - CANCER

KW - DEPSIPEPTIDE

KW - MANAGEMENT

U2 - 10.1200/JCO.2011.37.4223

DO - 10.1200/JCO.2011.37.4223

M3 - Original Article

C2 - 22271479

SN - 0732-183X

VL - 30

SP - 631

EP - 636

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 6

ER -

Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M et al. Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. JOURNAL OF CLINICAL ONCOLOGY . 2012;30(6):631-636. doi: 10.1200/JCO.2011.37.4223